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Abstract
Background: The activation of plasma enzyme systems contributes to hereditary angioedema attacks. We aimed to
study the activation markers of the fibrinolytic, coagulation, and contact systems in a larger number of paired
samples obtained from the same C1-INH-HAE patients in symptom-free periods and during attacks.
Methods: Eleven parameters (Factors XI, XII, and C1-inhibitor activity; the concentrations of the D-dimer, prothrombin
fragments 1 + 2, plasminogen, plasminogen activator inhibitor-1 [PAI-1], thrombin-anti-thrombin III [TAT] complex,
fibrinogen) were measured along with prothrombin time and activated partial thromboplastin time (aPTT),
using commercial kits. We compared these markers in samples obtained from the same 39 patients during attack-free
periods and during 62 edematous episodes. Forty healthy subjects of matching sex and age served as controls.
Results: Compared with the healthy controls, significantly higher FXI and FXII activity (p = 0.0007, p = 0.005), as well as
D-dimer (p < 0.0001), prothrombin fragments 1 + 2 (p < 0.0001), and TAT (p = 0.0303) levels were ascertained in the
patients during symptom-free periods. The evaluation of samples from symptom-free periods or obtained during attacks
revealed the increase of FXII activity, as well as of the concentration of D-dimer, prothrombin fragments 1 + 2, and TAT
during edematous episodes. PAI-1 level, prothrombin time, and aPTT decreased significantly during attacks, compared
with symptom-free periods. D-dimer level was significantly higher during multiple- vs. single-site attacks.
Conclusions: Comparing a large number of paired samples from symptom-free periods or from edematous episodes
allowed accurate appraisal of the changes occurring during attacks. Moreover, our study pointed out that individual
episodes may be characterized by different marker patterns.
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Background
C1-inhibitor (C1-INH) – the deficiency of which causes
hereditary angioedema (C1-INH-HAE) types I and II –
is a regulator of the complement, contact, coagulation,
and fibrinolytic systems, as it inhibits rapidly activated
factor XII (FXIIa), activated factor XI (FXIa), and kalli-
krein [1–5]. The contact system, also known as the
plasma kallikrein-kinin system, consists of factor XII,
prekallikrein, high-molecular-weight kininogen (HK),
and factor XI. Factor XII can be activated by contact
with negatively charged surfaces, extracellular RNA [6],
misfolded proteins [7], inorganic polyphosphates re-
leased from bacteria [8, 9], and bacterial surfaces [10].
When proteins of the contact system bind to endothe-
lial cells, the activation of factor XII leads to the conver-
sion of prekallikrein to kallikrein [11], which in turn
reciprocally activates factor XII. Furthermore, physical
trauma and surgery (known trigger factors of C1-INH-
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HAE) [12] can activate the contact system via the stress-
induced release of HSP-90, or the direct endothelial cell
activation of circulating factor XII, during which large
areas of endothelium are exposed [13]. Moreover, these
stimuli are important activators of the coagulation cas-
cade through the expression of tissue factor and the acti-
vation of factor VII [14]. Activated factor XII can initiate
blood coagulation via factor XI that links the extrinsic
and intrinsic arms of the coagulation system. Factor XI
circulates bound to high-molecular-weight kininogen in
the plasma, and it is activated by FXIIa. FXIa in turn can
activate factor XI, thereby contributing to the formation
of a fibrin clot, and also to thrombin generation via the
intrinsic pathway of coagulation. Remarkably, thrombin
may increase vascular permeability by the cleavage and
activation of a thrombin-susceptible receptor on the
endothelial cell surface. Binding induces intercellular gap
formation [15], which leads to edema [14, 16, 17].
Once activated by factor XII, kallikrein cleaves its en-
zyme cofactor, high-molecular-weight kininogen, leading
to the release of the vasoactive substance, bradykinin –
the key mediator of edematous attacks. The binding of
bradykinin to the bradykinin B2 receptor on the surface
of endothelial cells activates several intracellular signal-
ing pathways that induce vasodilatation, as well as in-
crease vascular permeability and fluid efflux [18, 19].
Furthermore, bradykinin can stimulate the release of tis-
sue plasminogen activator in the human vasculature
[20]; it also suppresses PAI-1 gene expression [21].
Additionally, kallikrein activates the fibrinolytic system
either directly – by converting plasminogen to plasmin
[22–24], or indirectly – by activating tissue-type (tPA)
and urokinase-type (uPA) plasmin activators, which convert
plasminogen to plasmin. Interestingly, plasmin can activate
factor XII to factor XIIa as an alternative to the kallikrein
feedback [25]. In vitro studies showed that plasmin en-
hances the production of bradykinin through the action of
kallikrein on high-molecular-weight kininogen [26].
Previous studies have analyzed the changes that
occur during C1-INH-HAE attacks in each plasma
enzyme system separately. According to their findings
activation of the plasma enzyme systems occurs dur-
ing attacks as suggested by the elevated levels of
cleaved HK, FXIIa, activated factor VII [14, 27, 28],
prothrombin fragments 1 + 2 (a marker of thrombin
generation), and D-dimer (a marker of fibrin degrad-
ation) [14, 29]. Despite all these facts, thrombotic
complications during the attacks, or increased throm-
botic risk in patients with C1-INH-HAE are not char-
acteristic, even though the activation of the contact
system is poorly regulated. It is hypothesized that in
patients with C1-INH-HAE, the activation of factor
XII preferentially triggers prekallikrein activation, ra-
ther than the production of FXIa by FXIIa.
Although the studies mentioned in the foregoing were
milestones in the exploration of the pathomechanism of
C1-INH-HAE, they had their limitations. They enrolled
only a small number of C1-INH-HAE patients, and usu-
ally did not compare the symptom-free and during-attack
states of the same patients. Furthermore, measuring the
components of the plasma enzyme systems separately has
the disadvantage that the results of the assays do neither
reflect the true balance between the activators and inhibi-
tors in the original blood sample, nor the interaction of
the four plasma enzyme systems. In our study, we tried to
overcome these limitations by the simultaneous evaluation
of the changes occurring in the coagulation, fibrinolytic,
and kinin-kalllikrein systems during C1-INH-HAE epi-
sodes. Furthermore, we compared this large set of param-
eters in the same patients during symptom-free periods





Thirty-nine C1-INH-HAE patients (12 men and 27
women, median age: 35 years, 25 to 75th percentiles: 22–
50 years), 33 with type I, and 6 with type II of C1-INH-
HAE, were enrolled into our study. In each patient, the
diagnosis was established according to the accepted clin-
ical and laboratory criteria (positive family history, clinical
symptoms of angioedema, low functional C1-INH level,
low C4, normal C1q concentrations) [30]. Human plasma-
derived C1-INH concentrate (pdC1-INH); Berinert®, CSL
Behring, Marburg, Germany) was available as an acute
remedy for edematous attacks. All patients received
pdC1-INH concentrate whenever this was necessary to re-
lieve the most severe forms of edematous episodes (i.e.
upper airway, abdominal, facial, genital, and severe limb
edema, predominantly). Seventeen patients (6 male and
11 female) received long-term prophylaxis during the
study period; thirteen of them were on long-term prophy-
laxis with danazol, and four of them were on tranexamic
acid. Twenty-two patients have not been on long-term
prophylaxis.
The “symptom-free samples” were collected during the
annual control visits, in case at least two weeks elapsed
since the date of the last attack. Furthermore, 62 sam-
ples in total were collected from the patients during
edematous attacks, before administering pdC1-INH con-
centrate (at least one, but not more than 5 “during-attack”
samples were obtained per patient). The severity and the
site of edematous attacks, as well as the time from onset
to blood sampling were recorded in the Hungarian HAE
Registry. The distribution of attack sites was as follows:
30.6 % (19/62) – abdominal region, 24.3 % (15/62) – arm,
19.3 % (12/62) – subcutaneous and submucosal locations
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simultaneously, 9.7 % (6/62) – leg, 8.1 % (5/62) – trunk,
4.8 % (3/62) – face, 3.2 % (2/62) – upper airways.
Healthy controls
The control group consisted of 40 healthy adults (15
men and 25 women, median age: 33 years, 25 to 75th
percentiles: 21–58 years). All subjects had been referred
for routine medical evaluation, and volunteered for the
study by giving informed consent. The healthy controls
did not have any known disease, or receive medicinal
products at the time of blood sampling. C1-INH defi-
ciency was excluded by complement testing in all
healthy subjects.
C1-INH-HAE patients and controls were not statisti-
cally different as regards age and gender distribution.
Blood sampling
Serum and citrated plasma samples obtained from pa-
tients with C1-INH-HAE in symptom-free periods and
during attacks were stored at −80 °C until processing.
Peripheral blood samples were drawn also from the
healthy subjects, as prescribed by the study protocol.
The latter was approved by the institutional review
board of Semmelweis University of Budapest, and in-
formed consent was obtained from the participants in
accordance with the Declaration of Helsinki.
Measurement of the parameters related to the contact,
fibrinolytic, coagulation, and complement systems
All analyzed parameters were determined using the
same, unthawed aliquot from each subject and each
assay was performed on aliquots thawed for the same
time. Commercial kits were used to determine the activ-
ity of C1-INH in serum (Quidel, San Diego, USA), and
in citrated plasma the coagulation markers (prothrombin
fragments 1 + 2 and thrombin-antithrombin complex,
Enzygnost), the proteins of the fibrinolytic system
(plasminogen: Berichrom Plasminogen kit, and PAI-1:
Berichrom), the activation marker of fibrinolysis (D-
dimer, Innovance D-dimer kit), as well as the activity of
factor XI (Siemens Healthcare Diagnostics) and factor
XII (Siemens Healthcare Diagnostics), according to the
manufacturer’s instructions. Prothrombin time and ac-
tivated partial thromboplastin time (aPTT) were deter-
mined by standard laboratory methods in citrated
plasma. The level of fibrinogen was determined using
the Clauss method using citrated plasma, where high
levels of thrombin are added to diluted plasma and the
time it takes for that thrombin to convert fibrinogen to
fibrin correlates to the concentration of fibrinogen [31].
Statistical analysis
The statistical calculations were performed with Prism
for Windows v5.02 (GraphPad Software Inc., San Diego,
CA, www.graphpad.com), and SPSS v13.0 (SPSS Inc.,
Chicago, IL). Mann–Whitney’s U-test was used to com-
pare two independent groups (C1-INH-HAE patients vs.
healthy controls), whereas the Wilcoxon test was chosen
to compare the “symptom-free” and “during-attack”
results of the same patients. If a patient had several
“during-attack samples”, a mean value was calculated for
paired statistical comparison. In order to take into ac-
count all attack samples, a linear mixed model (LMM)
was fitted to estimate the changes between the “symp-
tom-free” and “during-attack” states of the same pa-
tients. This model permits including all the data
obtained during various attacks of different patients
(random effects), and even allows for missing data. In
this model, the “symptom-free” or the “during-attack”
(type of sample) was included in the LMM as a fixed ef-
fect, whereas patient ID, and the number of successive
attacks were included as random effects to adjust for
correlation among repeated measures within the sub-
jects. The different markers of the contact, fibrinolytic,
coagulation, and complement systems were each in-
cluded as a dependent variable in the LMM.
When calculating correlations using Spearman’s rho,
each patient was characterized by a random value for
each parameter. All the statistical analyses were two-
tailed, and p < 0.05 was considered to represent a signifi-
cant difference, or correlation.
Results
Evaluation of coagulation parameters in symptom-free
periods and during attacks, in the same C1-INH-HAE
patients
In order to analyze the activation of the coagulation cas-
cade during edematous attacks – as it had been suggested
previously – we determined the plasma coagulation
parameters in samples collected from the same C1-INH-
HAE patients in symptom-free periods and during attacks.
Then, we compared their results to the values of healthy
subjects.
The activity of factor XII was enhanced in the
symptom-free period, compared with that observed in
the healthy subjects (p = 0.0050), and increased further
significantly during attacks (paired t-test, p = 0.0314) in
the same C1-INH-HAE patients (Fig. 1a).
Interestingly, the activity of factor XI was significantly
elevated in C1-INH-HAE patients, both in the symptom-
free period (p = 0.0007) and during attacks (p < 0.0001),
compared with that seen in the healthy subjects. However,
no further elevation was ascertained during attacks, in
comparison to the symptom-free period (Fig. 1b).
The concentration of prothrombin fragments 1 + 2 was
elevated in the symptom-free period compared with the
healthy subjects (p < 0.0001), and increased significantly
Csuka et al. Orphanet Journal of Rare Diseases  (2015) 10:132 Page 3 of 13
further in the same patients during attacks (paired t-test,
p = 0.0005) (Fig. 1c).
Although we could not find a difference in prothrom-
bin time between C1-INH-HAE patients and healthy
subjects, prothrombin time was significantly shorter dur-
ing attacks, compared with the symptom-free period
(paired t-test, p = 0.0026) (Fig. 1d).
Interestingly, activated partial thromboplastin time was
shorter, both in the symptom-free period (p = 0.0001) and
during attacks (p < 0.0001), compared with the healthy
controls. A further decrease was observed during attacks,
compared with the symptom-free period (paired t-
test, p = 0.0096) (Fig. 1e).
The level of thrombin-antithrombin complexes was
higher both in symptom-free (p = 0.0303) and in symp-
tomatic (p < 0.0001) C1-INH-HAE patients, compared
with the controls. We detected a stepwise elevation in
its level from the symptom-free period to the attacks
(paired t-test, p = 0.0028) (Fig. 1f ).
Analysis of the markers and proteins of fibrinolysis in
symptom-free periods and during attacks in the same
C1-INH-HAE patients
The concentration of fibrinogen was slightly elevated
during attacks, compared with the symptom-free period
(p = 0.012) (Fig. 2a), but no significant difference was
found between healthy subjects and patients during the
symptom-free period. D-dimer level showed a significant
elevation both in the symptom-free period (p < 0.0001)
and during attacks (p < 0.0001), compared with the
healthy subjects. Furthermore, its level increased further
during attacks (paired t-test, p < 0.0001), compared with
the symptom-free period of the same patients (Fig. 2b).
By contrast, the level of plasminogen activator
inhibitor-1 (PAI-1) was lower during attacks than in the
symptom-free period (paired t-test, p = 0.0040), or in the
healthy subjects (p = 0.0213) (Fig. 2d).
We could not find any difference between the study
groups as regards plasminogen level (Fig. 2c).
We applied a mixed linear model to analyze the
changes of the parameters of the fibrinolytic, coagula-
tion, and kinin-kallikrein systems during attacks, in
comparison with reference samples (obtained in an
attack-free period). This model permits including all the
data obtained during successive attacks of different pa-
tients (random effects), and even allows for missing data.
We found the corresponding values from the symptom-
free and during-attack states (fixed effect) to be signifi-
cantly different, which confirms the results of the paired
t-test performed beforehand (Table 1).
Fig. 1 Evaluation of coagulation parameters in symptom-free periods and during attacks in the same C1-INH-HAE patients(Panels a-f). Each
patient is represented by a single value, which was calculated as the mean in case several attacks had occurred. The results of the patients and
those of the healthy controls were compared using the Mann–Whitney test; whereas the “symptom-free” or “during attack” results of the same
patients were compared with the paired t-test
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Correlations among the study parameters of healthy
controls and of C1-INH-HAE patients in the symptom-free
period and during attacks
Next, we evaluated the correlations between the study
parameters. In healthy subjects, the closest correla-
tions were found between aPTT and the activity of
factor XI (R = −0.5391, p = 0.0003), the activity of factor XII
(R = −0.5547, p = 0.0002), prothrombin time (R = 0.6988,
p < 0.0001), the level of fibrinogen (R = −0.6643, p < 0.0001),
and C1-INH activity (R =−0.5632, p = 0.0003). Further-
more, the activity of C1-INH correlated significantly with
that of factor XI (R = 0.4744, p = 0.0035) and with fibrino-
gen level (R = 0.4681, p = 0.0040) (Fig. 3a).
In the analyses of the correlations identified in C1-
INH-HAE patients, each patient was represented by a
random value. In symptom-free patients, we found
closer correlations, for instance between aPTT and fac-
tor XI (R = −0.7077, p < 0.0001), factor XII (R = −0.7596,
Fig. 2 Analysis of the proteins and markers of fibrinolysis in symptom-free periods and during attacks in the same C1-INH-HAE patients (Panels
a-d). Each patient is represented by a single value that was calculated as the mean in case several attacks had occurred. The results of the
patients and of the healthy controls were compared using the Mann–Whitney test; whereas the “symptom-free” or “during attack” results of the
same patients were compared with the paired t-test. PAI-1 levels were available only from 12 healthy subjects
Table 1 The median levels of the proteins and markers of plasma enzyme systems in symptom-free periods and during attacks in
the same C1-INH-HAE patients. The Linear Mixed Model was used on all measured parameters to simulate random effects and repeated
measures, as well as to detect differences between the “symptom-free” and the “during-attack” states of the same patients
Dependent variable Estimatea 95 % Confidence interval P-valuea
Lower limit Upper limit
Factor XII, % 5.657 5.644 5.671 0.019
Factor XI, % 4.365 4.350 4.380 0.118
Prothrombin fragments 1 + 2, pmol/L 387.251 386.257 388.245 0.001
Prothrombin time, sec −0.533 −0.534 −0.534 <0.0001
Activated partial thromboplastin time, sec −3.039 −3.041 −3.037 <0.0001
Thrombin-anti-thrombin complex, μg/L 4.981 4.971 4.991 0.004
Fibrinogen, g/L 0.414 0.414 0.414 0.012
D-dimer, mg/L 3.105 3.104 3.106 <0.0001
Plasminogen, % 1.731 1.721 1.741 0.361
Plasminogen activator inhibitor-1, U/ml −0.524 −0.525 −0.525 0.006
aFor the difference between the “during attack” and the “symptom-free” samples
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Fig. 3 Correlations among the study parameters in healthy controls (a) and in C1-INH-HAE patients during the symptom-free period (b), and
during attacks (c). Each patient is represented by one random value. Spearman’s rank correlation coefficient was calculated
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p < 0.0001), or fibrinogen (R = −0.5331, p = 0.0017). Fur-
thermore, fibrinogen level correlated significantly with
the activity of factor XI (R = 0.6378, p < 0.0001) or of fac-
tor XII (R = 0.4974, p = 0.0038), as well as with pro-
thrombin time (R = −0.4292, p = 0.0160). Significant,
positive correlations were found between the level of
prothrombin fragments 1 + 2 and the concentrations of
TAT (R = 0.5896, p < 0.0001), or D-dimer (R = 0.5222,
p = 0.0022) in the symptom-free period (Fig. 3b).
Interestingly, we found a different correlation pattern
during attacks, compared with that seen in the symptom-
free period. The relationship between the levels of pro-
thrombin fragments 1 + 2 and those of TAT became
stronger (R = 0.7756, p < 0.0001), whereas the correlation
between aPTT and factor XI (R = −0.6983, p < 0.0001) or
factor XII (R = −0.6870, p < 0.0001) remained nearly the
same. In contrast to the symptom-free period, the activity
of C1-INH showed significant negative correlations with
prothrombin time (R = −0.4905, p = 0.0128), and with
the level of prothrombin fragments 1 + 2 (R = −0.3758,
p = 0.0372) during attacks. Furthermore, D-dimer level
correlated significantly with the concentration of pro-
thrombin fragments 1 + 2 (R = 0.3899, p = 0.0274), or
of TAT (R = 0.3674, p = 0.0386) (Fig. 3c).
None of the parameters correlated significantly with
time from symptom onset to blood sampling.
Differences between the coagulation and the fibrinolysis
parameters, depending on attack location
We analyzed whether there is a difference between
“single-site” vs. “multiple-site” attacks, or between the
subcutaneous vs. submucosal episodes, as regards the
levels of the measured parameters.
Among all studied parameters, prothrombin time, D-
dimer and plasminogen levels showed significant differ-
ences between attacks that had occurred in a single site
vs. those involving multiple sites (Fig. 4).
During attacks occurring at multiple sites, the level of
D-dimer increased (p = 0.002), whereas prothrombin
time (p = 0.018) and plasminogen (p = 0.008) level de-
creased compared with the values of “single site” attacks
(Table 2).
Furthermore, the concentration of D-dimer de-
creased slightly during submucosal attacks, whereas
the level of plasminogen increased a little during sub-
mucosal compared with subcutaneous attacks. How-
ever, these differences were only of marginal significance
(p = 0.060; p = 0.051, respectively) (Table 2).
All these data suggest that the activation of the plasma
enzyme systems is more pronounced during attacks in-
volving multiple sites, compared with those occurring at
a single site. We could not find similar differences be-
tween the subcutaneous or submucosal location.
Coagulation and fibrinolysis parameters in successive
during-attack samples from the same patients
The severity and presentation of the manifestations of
C1-INH-HAE, as well as its possible triggering factors
exhibit considerable inter- and intra-individual variation.
Therefore, we examined the magnitude of the changes
and fluctuations in the study parameters during succes-
sive attacks experienced by the individual patients, as
well as the range of their variability in a given subject.
Eight patients (5 patients with C1-INH-HAE type I: Pts
N° 1–5, and 3 patients with C1-INH-HAE type II: Pts N°
6–8) had ≥1 during-attack samples (min. 2 samples,
max. 5 samples). This enabled us to monitor the changes
even between successive attacks occurring in the same
patient. Each “during-attack” value was divided by the
corresponding “inter-attack” value, and these ratios were
plotted as different symbols, according to the site of the
attack (Fig. 5).
We found differences between the patients as regards
the patterns of the coagulation and of the fibrinolysis pa-
rameters. In particular, the levels of fibrinogen, thrombin-
Fig. 4 Differences in the coagulation and fibrinolysis parameters depending on attack location(Panels a-c). The LMM was used to compare the
levels of the parameters during attacks occurring at a “Single site” vs. at “Multiple sites”, or in subcutaneous (SC) vs. submucosal (SM) location
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antithrombin complex, D-dimer, and C1-inhibitor showed
great variability among the study subjects (Fig. 5).
Furthermore, D-dimer level and the activity of the C1-
inhibitor showed large fluctuations even between succes-
sive attacks in the same patient (Fig. 5).
Discussion
Our aim was to perform a comprehensive study in a large
population of C1-INH-HAE patients, in order to investigate
the changes occurring in the plasma enzyme systems dur-
ing edematous attacks. In the current study, we simultan-
eously evaluated such changes in the coagulation, the
fibrinolytic, and the contact systems. Furthermore, we com-
pared this large set of parameters recorded from the same
patients in symptom-free periods and during attacks – that
is, each patient served as his/her own control. The design
of our study enabled us to conduct an investigation of un-
precedented comprehensiveness and complexity into the
changes accompanying C1-INH-HAE attacks. Figure 6 pro-
vides a comprehensive and schematic representation of the
changes that occur in the plasma enzyme systems during
edematous attacks.
In recent years, many studies have been published on
the activation of the plasma enzyme systems during her-
editary angioedema attacks. However, these included
only a small number of patients and in most cases, the
“symptom-free” and the “during attack” samples were
obtained from different subjects.
Based on our results, the activity of factor XII is
higher in the patients during the symptom-free period
than in the healthy subjects and it increases further
significantly during attacks; the latter is in accord
with previous findings [14, 32].
Although a previous study did not detect any difference
between healthy controls and C1-INH-HAE patients as
regards the level of factor XI [33], we ascertained signifi-
cant elevation of the latter in symptom-free C1-INH-HAE
patients. However, we could not detect any further in-
crease during attacks, compared with the symptom-free
period.
In agreement with previous studies [29, 34], the level
of prothrombin fragments 1 + 2 was higher in symptom-
free C1-INH-HAE patients than in healthy controls, and
it increased further in the same patients during attacks.
Intriguingly, patients with C1-INH deficiency and with
elevated levels of prothrombin fragments 1 + 2 (which
indicate a state of hypercoagulability) do not have an in-
creased risk for thrombotic events, as would be expected
in such a situation. We had not measured the levels of
coagulation inhibitors and thus, could not ascertain the
magnitude and direction of their changes – or the pos-
sible development of a steady state of some kind. It is
conceivable that the hyperfibrinolytic state, which we
confirmed in our current study, and that was demon-
strated in previous studies as the elevation of D-dimer
levels – is sufficient to counteract the observed hyperco-
agulability [14, 33, 35]. D-dimer is produced during the
breakdown of the fibrin mesh by plasmin. Therefore, in
the state of hypercoagulation, any clot that forms is
cleared by the fibrinolytic activity and thus, D-dimer is
generated. In the context of our study, this may mean
secondary hyperfibrinolysis, because the plasminogen
levels measured during symptom-free periods did not
differ from those determined in the healthy controls, or
from those recorded during edematous attacks. If a
major increase of hyperfibrinolysis would have occurred,
we should have detected decreased plasminogen levels.
Hypercoagulation, on the other hand, appeared promin-
ent – because its presence was indicated even by the re-
duction of prothrombin time and of aPTT. It should be
noted that the reduction of clotting times can be shown
only occasionally, although this succeeds sometimes in
disseminated intravascular coagulation [36]. In addition
to the decreased clotting times, the elevated levels of the
markers of the activation of coagulation were also char-
acteristic in our study during the attacks. Of these, pro-
thrombin fragments 1 + 2 indicates the formation of
thrombin, whereas the elevation of TAT level reflects
the neutralization of the formed thrombin by antithrom-
bin. As thromboembolic events did not occur in our
Table 2 Parameters of the coagulation and of the fibrinolytic system in symptom-free periods and during attacks, in the same
C1-INH-HAE patients. The Linear Mixed Model was used to simulate random effects and repeated measures, to detect differences
between the attacks occurring at a “Single site” vs. at “Multiple sites”, or in subcutaneous (SC) vs. submucosal (SM) location
Dependent variable Comparison made between: Estimatea 95 % Confidence interval P valuea
Lower bound Upper bound
Prothrombin time, sec Attack at single site vs. multiple sites −0.478 −0.590 −0.367 0.018
Attack in SC or SM location 0.052 −0.004 0.109 0.816
D-dimer, mg/L Attack at single site vs. multiple sites 3.504 2.699 4.308 0.002
Attack in SC or SM location −1.737 −1.953 −1.522 0.060
Plasminogen, % Attack at single site vs. multiple sites −16.619 −21.280 −11.960 0.008
Attack in SC or SM location 10.778 8.763 12.792 0.051
aFor the difference between the “during attack” and the “symptom-free” samples
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Fig. 5 (See legend on next page.)
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patients, it is possible that the thrombin thus formed is
kept under control by the inhibitors.
The decrease of thrombin time indicates activation of
the extrinsic pathway in the first place. However, judged
by the activation of factors XII and XI, activation of the
intrinsic pathway of blood coagulation is more typical.
This is the possible reason why the reduction of aPTT is
more conspicuous in symptom-free periods – and much
more during attacks – even in comparison with healthy
controls. To our best knowledge, activated partial
thromboplastin time was not studied previously. In our
study, we could detect a decreased level during the
symptom-free period, compared to the healthy subjects,
and its level decreased further during attacks.
One previous study did not find any difference be-
tween the TAT levels of healthy controls and of
symptom-free patients [33]. Notwithstanding this, we
detected a stepwise elevation in its level, both in the
symptom-free period, and during the attacks. Thrombin
generation appears to increase both in symptom-free/
symptomatic C1-INH-HAE patients (as shown by the el-
evated level of the relevant plasma marker, prothrombin
fragments 1 + 2). However, the effect of thrombin on
vascular permeability may be weaker in vivo, owing to
its rapid inactivation by anti-thrombin – as shown by
the elevated levels of the TAT complex in our study.
This inactivation may also explain why C1-INH-HAE
patients do not develop thrombosis during edematous
attacks.
To our best knowledge, the levels of fibrinogen and
plasminogen have not yet been studied before in C1-
INH-HAE patients. In our study, we could not find any
difference in these parameters between healthy subjects
and C1-INH-HAE patients. However, fibrinogen level
(See figure on previous page.)
Fig. 5 Distribution of the studied parameters during multiple attacks in the same patients with C1-INH-HAE. Factor XII (a), factor XI (b), prothrombin
time (c), activated partial thromboplastin time (d), prothrombin fragments 1 + 2 (e), thrombin-antithrombin complex (f), fibrinogen (g), plasminogen
(h), D-dimer (i) and C1-INH (j) were assessed in 8 patients with more than one “during attack” sample. Each “during attack” value was divided by the
corresponding inter-attack value, and these ratios were plotted as different symbols, according to the site of the attack. The medians of
the ratios are presented as a solid line. The ratio = 1 is presented as a dotted line. The values under the dotted line represent decreased
levels, whereas those above the dotted line correspond to elevated levels of the measured parameters. Meaning of the symbols: empty
symbols = single attack; filled symbols = multiple attacks
Fig. 6 Schematic representation of the plasma enzyme systems, including a summary of our results. Grey arrows show the difference between
healthy subjects and the symptom-free C1-INH-HAE patients, whereas black arrows show the difference between the symptom-free and the
“during attack” period of the same patient. Dotted lines highlight those parameters that were analysed in our study. ⊣ The symbol indicates an
inhibitory effect
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was slightly elevated during attacks, compared with the
symptom-free period – this may be explained by the fact
that fibrinogen is an acute phase protein [37, 38]. Re-
markably, PTT decreases during an acute phase reac-
tion, just as we have seen in the C1-INH-HAE patients
during attacks. Thus, the latter may be accompanied by
an acute phase reaction.
In our study, D-dimer (the plasma marker of fibrin
degradation) showed a significant elevation in the
symptom-free period compared with the controls; this is
in agreement with findings from previous studies [29, 34].
Interestingly, its level increased further during attacks of
the same patients – as shown by a previous study as well
[35]. At variance with a previous study, the level of
PAI-1 decreased continuously in the symptom-free
period and even further during attacks. However, no
difference was found previously between the symptom-
free and the symptomatic period [34]. As discussed by van
Geffen et al., decreased levels of PAI-1 may be a conse-
quence of enhanced thrombin production in association
with protein C activation, which leads to the consumption
of PAI-1 [34].
Taken together, our study confirmed the results of pre-
vious research into the activation of the coagulation sys-
tem (as shown previously by elevated levels of
prothrombin fragments 1 + 2) [33], as well as into the
activation of the fibrinolytic system (as shown previously
by the increased concentrations of D-dimer, TAFI,
thrombomodulin and plasmin-α2-antiplasmin complex)
[29, 34] in the symptom-free period.
Unlike the earlier studies [29, 33, 34], we detected dif-
ferences in multiple parameters (factor XI, D-dimer,
PAI-1) between the symptom-free and the during-attack
states. The likely explanation for these is the small num-
ber of patients evaluated in the previous studies, of
which only a few analyzed blood samples obtained from
the same patients during the symptom-free period as
well as during attacks.
The design of our study – that is, simultaneous evalu-
ation of the components of the various plasma enzyme
systems in the same patients – enabled us to investigate
the correlations within and between the individual
enzyme systems as far as the study parameters are con-
cerned. We described for the first time that in C1-INH-
HAE patients, the interactions among the plasma
enzyme systems change both during symptom-free pe-
riods and during attacks, as suggested by the diverse
correlation patterns, compared with the healthy subjects.
The correlation between aPTT and factor XI or factor
XII was present in all three sets of data (healthy subjects,
symptom-free C1-INH-HAE, during attack C1-INH-
HAE). Factor XII and aPTT exhibited a significant,
negative correlation (which was the weakest in healthy
subjects). This means that the higher is the level of
factor XII, the shorter (smaller) is aPTT, and coagula-
tion time decreases accordingly. However, this mech-
anism is possibly counterbalanced by the activation of
the fibrinolytic system, as suggested by our results
and by previous studies [14, 33, 35]. In healthy
subjects, the C1-inhibitor – the key regulator in C1-
INH-HAE – correlated with aPTT, the activity of
factor XI, and with fibrinogen level. Interestingly, C1-
INH activity showed no correlation in the symptom-
free period, but during attacks, its activity exhibited a
significant negative correlation with prothrombin time,
or with the level of prothrombin fragments 1 + 2. The
latter observation may indicate the involvement of the
activation of the coagulation system during C1-INH-
HAE attacks, in agreement with the findings of a pre-
vious study [34]. During attacks, the relationship
between prothrombin fragments 1 + 2 and TAT be-
came stronger than that observed in the symptom-
free period. Despite this, the relationship between the
levels of the D-dimer and of the prothrombin frag-
ments 1 + 2 became weaker during attacks, compared
with that seen in the symptom-free period. We can
conclude that the strongest correlations were found
in HAE-C1-INH patients during the symptom-free
period.
The novelties of our study include the comparison of
several plasma enzyme system components between at-
tacks occurring at single vs. multiple sites, and in sub-
cutaneous vs. submucosal locations. During attacks with
multiple sites, we observed enhanced activation of the
plasma enzyme systems, compared with attacks re-
stricted to a single site. This was reflected by the signifi-
cant elevation of D-dimer levels (that was also shown by
Reshef et al.) [35], and by the decreased prothrombin
time and plasminogen concentration in multiple-site at-
tacks. Interestingly, we could not find any difference in
the study parameters between subcutaneous and sub-
mucosal attacks. To our best knowledge, two studies
have analyzed so far the possible differences between
subcutaneous vs. submucosal attacks [29, 35], and only
one of them showed significant difference in the level of
D-dimer between these two locations [35].
As several during-attack samples were available from
the same C1-INH-HAE patients, we analyzed whether
there is a fluctuation between the attacks occurring in
different patients, or between the successive attacks of
the same patient. Interestingly, we found differences
between the patients as regards the patterns of coagula-
tion and fibrinolysis markers, namely in the levels of fi-
brinogen, thrombin-antithrombin complex, D-dimer
and C1-inhibitor showed large inter-individual varia-
tions. Furthermore, D-dimer level and the activity of
the C1-inhibitor exhibited a large fluctuation between
the successive attacks of the same patient.
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Conclusions
The strengths of our study include the comparison of a
large number of paired samples from symptom-free periods
or from edematous episodes of the same patients, as well as
the parallel monitoring of the parameters of the plasma en-
zyme systems. This approach allowed accurate appraisal of
the changes occurring during C1-INH-HAE attacks. More-
over, our study pointed out that the individual edematous
episodes may be characterized by different marker patterns
among the studied individuals. We also showed that attacks
with multiple sites are characterized by more enhanced ac-
tivation of the plasma enzyme systems, compared with at-
tacks restricted to a single site.
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